

Novel TB diagnostics

Dr Jane Cunningham

Infectious Diseases and Microbiology Specialty Registrar

Sheffield University Teaching Hospital

UK

Dr Roslin Russell
Cambridge Institute
University of Cambridge
Cambridge

Dr Oliver Stegle
Team Leader
European bioinformatics Institute
Cambridge

ProteinLogic
■ ■ ■ ■ ■ ■ ■ ■ ■ ■ *Pattern-based medicine*

Today's biomarkers for tomorrow's healthcare



Background



Today's biomarkers for tomorrow's healthcare

TB signature development

Sample numbers (Total = 405)

	Pilot study Uganda	London 2011	London 2012	London 2012
Active disease	20 AFB positive	40 pTB & EPTB	7	94 pTB & EPTB
	20 AFB/HIV positive			
Asymptomatic	20			
Asymptomatic IGRA Positive		40		89
Asymptomatic IGRA Negative		30	16	
Sick control			8 (Atypical Mycobacteria)	21



AUC summary for initial samples

	Healthy Ctrl/TB	Active /Latent	Sick Ctrl/TB	Sick 2 /TB	Sick 2 /Active	Sick2 /Latent
Markers 6 & 7	73% (0.03)	88% (0.01)	71% (0.02)	69% (0.07)	87% (0.03)	61% (0.05)
Combined Markers 1-8	91% (0.01)	90% (0.00)	73% (0.05)	73% (0.03)	87% (0.04)	60% (0.01)

TB = Active + latent disease
 Sick 2 = Sick control – atypical Mycobacteria

Reported are area under the curves (AUC) and +- 1 standard deviation estimated from 3 repeat experiments.



TB signature development Selection strategies

- Early discovery panel (multiplexed panel)
- Literature information
- Biological/immunological plausibility
- Microarray studies




TB Prediction

Independent test cohorts (Total = 420)

	Healthy	Latent	Active (smear pos)	Active (smear neg)	Sick
South Africa	26	68	100		
Vietnamese		47	92	47	44



Classification: Random Forest



AUC Summary

Prediction	Specifics	Country	AUC (all)	AUC (best)
Sick/Active TB	Smear pos	VN	89.2	91.6
	Smear neg	VN	79.4	83.6
	All	VN	86	89.5
Active/Latent	All	VN	91.8	94.3
	Smear pos	SA	99.8	100
	Smear pos	VN	97.2	98.5
	Smear neg	VN	77.8	87.7
Healthy/Active	Smear pos	SA	100	100.0
Sick/Latent		VN	57.9	71.0




Comparison of ProteinLogic Test vs WHO TPP for Triage Test

		TPP	ProteinLogic
Sensitivity	Sputum positive	>90-95%	95%
	Sputum negative	>90-95%	91.5%
	EPTB	-	-
Specificity	Sputum positive	>70-80%	72%
	Sputum negative	>70-80%	56.8%
	EPTB	-	-



AFB sputum positive, culture positive vs sick control




	Result
SENS	95%
SPEC	72%
PPV	62.68 %
NPV	97.10 %

AFB & Culture + ve: N = 192
 Sick N = 44



AFB sputum negative, culture positive vs sick control




	Result
SENS	91.5%
SPEC	56.8%
PPV	69.3%
NPV	86.2%

△ AFB -ve & culture +ve N = 47
 Sick N = 44



AFB sputum positive, culture positive vs healthy control




	Results
Sens	100%
Spec	100%
PPV	100%
NPV	100%

AFB & culture +ve:
 N = 192
 Healthy control: N= 26



Culture positive vs latent TB



	Results
Sens	100
Spec	97.2
NPV	100
PPV	95.2

Culture +ve: N = 239

Latent: N= 115



Prediction	Specifics	Country	AUC (all) Method 1	AUC (best) Method 2	AUC Method 3
Active/Latent		South Africa	100	100	98.9
Active/Latent		Vietnam	89	94.3	94.9
Active/Latent	Smear positive	Vietnam	95	98.5	98.5
Active/Latent	Smear negative	Vietnam	80	87.7	89.2



Diagnostic landscape

- Rule out test used as first line to Xpert.
- IGRA plus.
- Progression from latent to active.
- Response to treatment.
- Novel pathways for vaccine development.
- Second generation definitive diagnostic.



Acknowledgements

- Prof Keertan Dheda
- Prof Ajit Lalvani
- Dr Adrian Martineau
- Ugandan pilot team
 - Prof LA Wilson
 - Dr Conrad Muzoora
 - Dr Dennis Okumu
 - Dr Michael Hunter
- FIND
- Dr Keith Burling
- Prof Herman Waldman
- Sir Gregory Winter
- Dr Adrian Woolfson

